MedPath

Impact of Oral Zinc Supplementation on Serum Bilirubin Levels in Neonates with Hyperbilirubinemia Undergoing Phototherapy: An Open-Label Randomized Controlled Trial

Phase 2
Conditions
Health Condition 1: P84- Other problems with newborn
Registration Number
CTRI/2024/08/071828
Lead Sponsor
Dr Supreeth sv
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

All late preterm(=35weeks), term, post term neonates admitted with hyperbilirubinemia in phototherapy range.

Exclusion Criteria

Neonates with direct hyperbilirubinemia

• Major gross congenital anomalies (gastrointerstinal malformations, heart defects, neural tube defects) and with identifiable genetic syndromes.

• Preterm neonate(=35weeks), who are already started on zinc supplementation

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath